WALTHAM, Mass., March 16, 2016 (GLOBE NEWSWIRE) -- Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases that reduce longevity and life quality, today announced the appointment of leading experts to its newly formed Clinical Advisory Board to advise the Company on clinical programs aimed at demonstrating the clinical and health economic benefits of targeted prevention and treatment of periodontitis, a common local inflammatory disease, in the management of several chronic diseases that affect widespread tissues and organs of the body.
“We are extremely pleased to bring together a ‘dream team’ of international experts at the intersection of systemic and oral health, to advise Interleukin Genetics on building evidence and care pathways, and the dissemination of practical clinical approaches to capture medical value,” said Dr. Kenneth Kornman, President and Chief Scientific Officer of Interleukin Genetics.
The Board will be chaired by Sir Gordon W. Duff, MD, PhD, Florey Professor of Molecular Medicine Emeritus, and former Director of the Division of Genomic Medicine in the School of Medicine at the University of Sheffield in the United Kingdom, and the former Chair of the UK’s regulatory agency, the Medicines and Healthcare Products Regulatory Agency (MHRA), the UK equivalent of the U.S. Food and Drug Administration. Sir Gordon is a pioneer in genetics of inflammation and has also been Chair of the UK’s National Institute for Biological Standards and Control.
The inaugural members of Interleukin Genetics’ Clinical Advisory Board include:
- Sir Gordon Duff, MD, PhD, St. Hilda’s College, University of Oxford
- Gary Armitage, DDS., University of California, San Francisco, School of Dentistry
- William Giannobile, DDS, MS, DMSc, University of Michigan School of Dentistry
- Steven Offenbacher, DDS, PhD, University of North Carolina School of Dentistry
- Panos Papapanou, DDS, PhD, Columbia University College of Dentistry
- Mariano Sanz, MD, DDS, University of Complutense of Madrid
“We are at an exciting point in our ability to enhance management of chronic inflammatory diseases,” said Sir Gordon. “Genetic and phenomic data combined with today’s computational power enable risk-stratification to target care in population health initiatives. Management of highly prevalent inflammatory diseases such as periodontitis may provide a practical access point to change the trajectory of other chronic conditions that impose a high burden on individual and public health. I look forward to working with the international clinical leaders on this new Board to help advance their innovative and important work in this field.”
Periodontal disease is one of most common chronic inflammatory diseases in developed countries, and better control of the condition has been shown significantly to lower the systemic inflammatory burden. In recent years, studies from multiple medical and dental insurance companies have reported that treatment or prevention of periodontitis was associated with substantial reduction in the cost of management of several chronic diseases, including type 2 diabetes and coronary artery disease.
"The launch of Interleukin Genetics’ Clinical Advisory Board underscores our commitment to the practical application of genetics to population health,” said Mark Carbeau, Chief Executive Officer of Interleukin Genetics. “The quality of the Board members is a great testament to the increasingly recognized importance of integrating medical and dental sciences in a more holistic approach to health.”
About Interleukin Genetics
Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions, and for informing lifestyle choices to facilitate wellness. Our tests provide information that is not otherwise available to empower individuals and their healthcare providers to manage their health and wellness through genetics-based insights and actionable guidance. Interleukin Genetics leverages its research, intellectual property, and genetic panel development expertise in inflammation and metabolism to identify individuals whose risk for certain chronic disease may be increased due to variants in one or more genes, which can enable a more targeted approach to the individual’s healthcare. The company markets its tests through healthcare professionals, partnerships with health and wellness companies, and other distribution channels. Interleukin Genetics’ lead products include its proprietary PerioPredict® genetic test that identifies individuals at risk for severe periodontal disease and a life-long predisposition to overproduce inflammation, and its Inherent Health® line of genetic tests. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvements Amendments (CLIA). For more information, please visit www.ilgenetics.com.
Certain statements contained herein are “forward-looking” statements. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in Interleukin’s annual report on Form 10-K for the year ended December 31, 2014, and other filings with the Securities and Exchange Commission. Interleukin disclaims any obligation or intention to update these forward-looking statements.
Source:Interleukin Genetics, Inc.